This website uses cookies, including third party ones, to allow for analysis of how people use our website in order to improve your experience and our services. By continuing to use our website, you agree to the use of such cookies. Click here for more information on our Cookie Policy and Privacy Policy.
close
Continue

Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Plan Your Visit

Bringing international communities together

Science. Debates. Collaboration

Why Japan?

  • New regulatory changes are already showing evidence that Japanese regulators actively support biotech innovation and give green light for companies who want to partner and conduct clinical trials in the region.

  • Japan became the new global epicentre for cell therapy after approving the Act on the Safety of Regenerative Medicine (ASRM) which provided a progressive new framework for development and approval of regenerative medicine products. 

  • In September 2015 Japanese regulators approved Terumo’s innovative ex vivo product Heartsheet® for treating severe heart failure caused by chronic ischemic heart disease and Mesoblast Ltd. in partnership with JCR Pharmaceuticals Co. Ltd.’s allogeneic mesenchymal stem cell product TemCell® HS Inj. for use in Acute Graft-versus-Host Disease which is to be used after bone marrow or hematopoietic stem cell transplants.

  • A handful of companies have ventures underway in Japan, including Athersys, RepliCel, Pluristem, and Mesoblast. In March, Athersys announced a partnership with Japan’s Chugai Pharmaceuticals to develop MultiStem to treat ischemic stroke patients in Japan. RepliCel and its Japanese partner Shishedo already have trials underway for RCH-01, a therapy to reverse pattern baldness in men and women.

Reduced rate accommodation

KNect 365 does not have a third party hotel booking agency representing this event aside from the below links. If you are contacted to book accommodation by any agency, this is not recommended as they are unknown to KNect 365 and the hotel.